

Comment

Comment on Li et al. *BDP1* Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. *Diagnostics* 2021, *11*, 2364

Laura Schramm D

Department of Biological Sciences, St. John's University, New York, NY 11439, USA; schramml@stjohns.edu



Citation: Schramm, L. Comment on Li et al. *BDP1* Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. *Diagnostics* 2021, *11*, 2364. *Diagnostics* **2022**, *12*, 608. https://doi.org/10.3390/ diagnostics12030608

Academic Editor: Gustavo Baldassarre

Received: 14 January 2022 Accepted: 25 February 2022 Published: 28 February 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

In 2021, Li et al. published an article on *BDP1* variants and implications in pediatric neuroblastoma patients [1]. BDP1 (B-double prime 1) was characterized as a subunit of TFIIIB required for accurate initiation by RNA polymerase III [2,3]. Li et al. cite Gensler's study entitled "Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1" as evidence for the TFIIIB associated BDP1 subunit as playing a key role in breast cancer [4]. In Gensler's work, the BDP1 protein they refer to is brain-derived phosphatase 1, as noted in Gensler's abbreviation section [4]. Gensler et al. [4] state in the introduction of their manuscript that brain-derived phosphatase 1 (BDP1) belonged to the family of PEST-containing protein tyrosine phosphatases [5] and was characterized in 1996 before the human homolog of yeast BDP1 was cloned and characterized in 2000 [2,3]. The human TFIIIB BDP1 subunit has not been described as a PEST-containing protein tyrosine kinase. A universal nomenclature for the RNA polymerase III initiation transcription factor TFIIIB complex was adopted in 2002 [6]. The official gene symbol for brain-derived phosphatase I approved by the Hugo Gene Nomenclature Committee is PTPN18 [7]. Li et al. should review the references cited demonstrating a role for BDP1 in human cancers [1]. The availability of genomics data makes it imperative for authors to strictly utilize the Hugo Gene Nomenclature Committee's approved nomenclature when analyzing available datasets and citing published research studies.

Funding: This research received no external funding.

Conflicts of Interest: The author declares no conflict of interest.

References

- Li, X.; Sun, L.; Stucky, A.; Tu, L.; Cai, J.; Chen, X.; Wu, Z.; Jiang, X.; Li, S.C. *BDP1* Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. *Diagnostics* 2021, 11, 2364. [CrossRef] [PubMed]
- Schramm, L.; Pendergrast, P.S.; Sun, Y.; Hernandez, N. Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters. *Genes Dev.* 2000, 14, 2650–2663. [CrossRef] [PubMed]
- 3. Schramm, L.; Hernandez, N. Recruitment of RNA polymerase III to its target promoters. *Genes Dev.* **2002**, *16*, 2593–2620. [CrossRef] [PubMed]
- 4. Gensler, M.; Buschbeck, M.; Ullrich, A. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. *J. Biol. Chem.* **2004**, 279, 12110–12116. [CrossRef] [PubMed]
- 5. Kim, Y.W.; Wang, H.; Sures, I.; Lammers, R.; Martell, K.J.; Ullrich, A. Characterization of the PEST family protein tyrosine phosphatase BDP1. *Oncogene* **1996**, *13*, 2275–2279. [PubMed]
- 6. Willis, I.M. A universal nomenclature for subunits of the RNA polymerase III transcription initiation factor TFIIIB. *Genes Dev.* **2002**, *16*, 1337–1338. [CrossRef] [PubMed]
- Povey, S.; Lovering, R.; Bruford, E.; Wright, M.; Lush, M.; Wain, H. The HUGO Gene Nomenclature Committee (HGNC). *Hum. Genet.* 2001, 109, 678–680. [CrossRef] [PubMed]

